Arbutus Biopharma Corporation (LON:0SGC)

Market Cap	512.65M
Revenue (ttm)	5.03M
Net Income (ttm)	-57.23M
Shares Out	n/a
EPS (ttm)	-0.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	756
Average Volume	1,640
Open	3.280
Previous Close	3.309
Day's Range	3.280 - 3.319
52-Week Range	1.788 - 3.734
Beta	n/a
RSI	49.03
Earnings Date	Feb 28, 2025

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company’s research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients’ HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, ...

• Industry: Biological Products, Except Diagnostic Substances
• CEO: Michael McElhaugh
• Employees: 73
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0SGC

Financial Performance

In 2023, Arbutus Biopharma's revenue was $18.14 million, a decrease of -53.51% compared to the previous year's $39.02 million. Losses were -$72.85 million, 4.89% more than in 2022.

Financial numbers in USD